212 related articles for article (PubMed ID: 20803231)
1. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.
Michaelis M; Paulus C; Löschmann N; Dauth S; Stange E; Doerr HW; Nevels M; Cinatl J
Cell Mol Life Sci; 2011 Mar; 68(6):1079-90. PubMed ID: 20803231
[TBL] [Abstract][Full Text] [Related]
2. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication.
Himmelsbach K; Sauter D; Baumert TF; Ludwig L; Blum HE; Hildt E
Gut; 2009 Dec; 58(12):1644-53. PubMed ID: 19710032
[TBL] [Abstract][Full Text] [Related]
3. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
4. Targeting Raf-kinase: molecular rationales and translational issues.
Caraglia M; Tassone P; Marra M; Budillon A; Venuta S; Tagliaferri P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii124-7. PubMed ID: 16760274
[TBL] [Abstract][Full Text] [Related]
5. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
7. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL
Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976
[TBL] [Abstract][Full Text] [Related]
8. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
[TBL] [Abstract][Full Text] [Related]
9. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Wei G; Wang M; Carr BI
J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
15. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Matsuda Y; Fukumoto M
Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
[TBL] [Abstract][Full Text] [Related]
17. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
18. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Matsuzawa Y; Kiuchi Y; Toyomura K; Matsumoto I; Nakamura H; Fujino H; Murayama T; Kawashima T
J Pharmacol Sci; 2009 Oct; 111(2):182-92. PubMed ID: 19783865
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F
PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]